Jon Congleton is President and Chief Executive Officer of Mineralys Therapeutics, Inc. (MLYS). The company reported total compensation of $5,544,727 for fiscal year 2025.
| Salary | $636,500 |
|---|---|
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $4,435,626 |
| Non-equity incentive plan | $472,601 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $0 |
| Total | $5,544,727 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Mineralys Therapeutics, Inc. filed April 8, 2026, accession 0001933414-26-000069.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | President and Chief Executive Officer | $636,500 | $0 | $0 | $4,435,626 | $472,601 | $0 | $0 | $5,544,727 |
| FY2024 | President and Chief Executive Officer | $580,000 | $0 | $0 | $4,537,818 | $303,050 | $0 | $0 | $5,420,868 |
Totals as disclosed in each year's own compensation disclosure for Mineralys Therapeutics, Inc..
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Jon Congleton this page | President and Chief Executive Officer | $5,544,727 |
| David Rodman | Chief Medical Officer | $2,204,704 |
| Adam Levy | Chief Financial Officer and Secretary | $2,203,096 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Mineralys Therapeutics, Inc. compensation brief.
Jon Congleton's compensation sits inside Mineralys Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.